← 返回

衔接蛋白 TRAF3 是一种抑制髓源性抑制细胞扩增的免疫检查点

英文原题:The adaptor protein TRAF3 is an immune checkpoint that inhibits myeloid-derived suppressor cell expansion.

查看英文原题

The adaptor protein TRAF3 is an immune checkpoint that inhibits myeloid-derived suppressor cell expansion.

PubMed 2023/05/03(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

髓源性抑制细胞(MDSCs)在癌症患者及其他病理条件下异常扩增。这些细胞协调免疫抑制和炎症网络,以促进癌症转移并介导患者对治疗的耐药性,因此被认为是人类癌症的重要治疗靶点。

在此,我们报道了接头蛋白TRAF3作为一种新型免疫检查点的鉴定,其关键性地限制了MDSC扩增。我们发现,髓系细胞特异性Traf3缺陷(M-Traf3-/-)小鼠在慢性炎症期间表现出MDSC过度扩增。有趣的是,M-Traf3-/-小鼠中MDSC的过度扩增导致移植肿瘤的生长和转移加速,并与T细胞和NK细胞表型改变相关。利用混合骨髓嵌合体,我们证明TRAF3通过细胞内在和细胞外在机制抑制MDSC扩增。

此外,我们阐明了MDSCs中的GM-CSF-STAT3-TRAF3-PTP1B信号轴,以及在炎症巨噬细胞和单核细胞中起作用的新型TLR4-TRAF3-CCL22-CCR4-G-CSF轴,二者协同调控慢性炎症期间的MDSC扩增。

综上所述,我们的发现为MDSC扩增的复杂调控机制提供了新见解,并为设计旨在靶向癌症患者MDSCs的新治疗策略开辟了独特视角。

展开英文摘要原文

Myeloid-derived suppressor cells (MDSCs) are aberrantly expanded in cancer patients and under other pathological conditions. These cells orchestrate the immunosuppressive and inflammatory network to facilitate cancer metastasis and mediate patient resistance to therapies, and thus are recognized as a prime therapeutic target of human cancers.

Here we report the identification of the adaptor protein TRAF3 as a novel immune checkpoint that critically restrains MDSC expansion.

We found that myeloid cell-specific Traf3 -deficient (M- Traf3 -/- ) mice exhibited MDSC hyperexpansion during chronic inflammation. Interestingly, MDSC hyperexpansion in M- Traf3 -/- mice led to accelerated growth and metastasis of transplanted tumors associated with an altered phenotype of T cells and NK cells. Using mixed bone marrow chimeras, we demonstrated that TRAF3 inhibited MDSC expansion via both cell-intrinsic and cell-extrinsic mechanisms.

Furthermore, we elucidated a GM-CSF-STAT3-TRAF3-PTP1B signaling axis in MDSCs and a novel TLR4-TRAF3-CCL22-CCR4-G-CSF axis acting in inflammatory macrophages and monocytes that coordinately control MDSC expansion during chronic inflammation. Taken together, our findings provide novel insights into the complex regulatory mechanisms of MDSC expansion and open up unique perspectives for the design of new therapeutic strategies that aim to target MDSCs in cancer patients.

论文信息

作者
Zhu S、Lalani AI、Jin J、Sant'Angelo D、Covey LR、Liu K、Young HA、Ostrand-Rosenberg S
单位
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States.United States
文献类型
美国 NIH 资助研究 · 美国 NIH 院内研究 · 非美国政府资助研究
期刊
Frontiers in immunology2023
原文标识
PubMed 37207205 · DOI 10.3389/fimmu.2023.1167924